Last reviewed · How we verify
Kamada-API
At a glance
| Generic name | Kamada-API |
|---|---|
| Sponsor | Kamada, Ltd. |
| Modality | Small molecule |
| Phase | Phase 2 |
Approved indications
Common side effects
Key clinical trials
- Phase III, Efficacy and Safety of "Kamada-AAT for Inhalation" (PHASE3)
- Phase II, Safety and Efficacy Study of Kamada-alpha-1-antitrypsin (AAT) for Inhalation" (PHASE2)
- International Study Evaluating the Safety and Efficacy of Inhaled, Human, Alpha-1 Antitrypsin (AAT) in Alpha-1 Antitrypsin Deficient Patients With Emphysema (PHASE2, PHASE3)
- Study Comparing Weekly Intravenous Administration of OctaAlpha1 With a Marketed Preparation Glassia® in Subjects With Alpha-1-antitrypsin Deficiency (PHASE2)
- Long Term Treatment Effect of the Safety, Tolerability and Efficacy of AAT in Type 1 Diabetes (PHASE2)
- Phase II/III Study of an Alpha-1 Proteinase Inhibitor (Kamada-API) in Individuals With Alpha-1 Antitrypsin Deficiency (PHASE2, PHASE3)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Kamada-API CI brief — competitive landscape report
- Kamada-API updates RSS · CI watch RSS
- Kamada, Ltd. portfolio CI